Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCND3 | P30281 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.39 |
| ▸ | TUBB | P07437 | 3/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139927 | 1.00 | CHEK1 (0.43) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL4151036 | 0.92 | BACE1 (0.40) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL4162242 | 0.92 | TUBB1 (0.43) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL4162243 | 0.92 | TUBB1 (0.43) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL4151031 | 0.92 | BACE1 (0.40) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL4146023 | 0.88 | AURKA (0.35) | CHEK1CCNA2CDK2KDRTUBB4A | |
| SCHEMBL4146020 | 0.88 | AURKA (0.35) | CHEK1CCNA2CDK2KDRTUBB4A | |
| SCHEMBL4145449 | 0.88 | RAB9A (0.39) | HPGDLMNAKDM4EALDH1A1POLB | |
| SCHEMBL4145446 | 0.88 | RAB9A (0.39) | HPGDLMNAKDM4EALDH1A1POLB | |
| SCHEMBL4154343 | 0.87 | CHEK1 (0.46) | CHEK1CDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | CHEK1 952/4885CDK4 256/4885CCNA2 538/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | CHEK1 657/4885CDK4 260/4885CCNA2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.